Maze Therapeutics, Inc. 8K

Maze Therapeutics appointed Paula Johnson and Sophie Kornowski to its Board of Directors to strengthen governance and support its advancing clinical pipeline.

On August 13, 2026, Maze Therapeutics, Inc. announced that Paula Johnson, M.D., M.P.H., President of Wellesley College and a current Johnson & Johnson board member, and Sophie Kornowski, Pharm.D., M.B.A., former CEO of Boston Pharmaceuticals and former Executive Vice-President of Roche Partnering, have been appointed to its Board of Directors, bringing additional clinical, academic, and biopharmaceutical industry expertise to support the company’s advancing kidney and metabolic disease pipeline and upcoming clinical milestones for its lead candidates MZE829 and MZE782.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

8K

Source Type

fda

Accession

0001193125-26-354092

Alert Tier

5